Annovis Bio, Inc.: management transactions · United States · SEC (Form 4)

About Annovis Bio, Inc.

Annovis Bio, Inc. is a U.S.-listed biotechnology company on the NYSE in the United States, focused on developing treatments for neurodegenerative diseases. Founded in 2008 and headquartered in Malvern, Pennsylvania, the company has evolved into a late-stage clinical biotech with a core research emphasis on Alzheimer’s disease and Parkinson’s disease. Its lead asset is buntanetap, an investigational once-daily oral therapy designed to target multiple neurotoxic proteins implicated in neurodegeneration. Scientifically, Annovis promotes a multi-target mechanism of action intended to affect pathways linked to amyloid pathology, tau, alpha-synuclein, and broader neuronal degeneration. That profile differentiates it from many competitors that still rely on narrower single-target approaches, although clinical and regulatory success remains unproven. The company does not yet have a diversified commercial business; it remains primarily a development-stage biotech whose valuation is driven by trial execution, FDA interactions, and financing capacity rather than by product sales. From a competitive standpoint, Annovis’ investment case is centered on clinical-stage momentum, intellectual-property protection, and the potential to convert a differentiated scientific narrative into late-stage regulatory progress. In 2025 and 2026, the company reported advancement of its Phase 3 early Alzheimer’s study and launched an open-label extension program in Parkinson’s disease. It has also highlighted work around additional neurological indications and patent activity related to buntanetap. These updates reinforce that the company’s value creation strategy is tied to clinical validation and regulatory milestones. Geographically, Annovis is largely U.S.-based, with its research, financing, and clinical trial activity concentrated in the United States. For investors, ANVS should therefore be viewed as a high-beta biotech story whose share performance is likely to be driven more by trial data than by traditional operating metrics. Recent highlights include an April 2026 financing that extended cash runway and ongoing enrollment progress in its Phase 3 programs, both of which are important for near-term market sentiment and longer-term strategic optionality.